www.nature.com/emi

ORIGINAL ARTICLE

EV71-infected CD14⁺ cells modulate the immune activity of T lymphocytes in rhesus monkeys

Jingjing Wang*, Jing Pu*, Hongtai Huang*, Ying Zhang, Longding Liu, Erxia Yang, Xiaofang Zhou, Na Ma, Hongling Zhao, Lichun Wang, Zhenfeng Xie, Donghong Tang and Qihan Li

Preliminary studies of the major pathogen enterovirus 71 (EV71), a member of the *Picornaviridae* family, have suggested that EV71 may be a major cause of fatal hand, foot and mouth disease cases. Currently, the role of the pathological changes induced by EV71 infection in the immunopathogenic response remains unclear. Our study focused on the interaction between this virus and immunocytes and indicated that this virus has the ability to replicate in CD14⁺ cells. Furthermore, these EV71-infected CD14⁺ cells have the capacity to stimulate the proliferation of T cells and to enhance the release of certain functional cytokines. An adaptive immune response induced by the back-transfusion of EV71-infected CD14⁺ cells was observed in donor neonatal rhesus monkeys. Based on these observations, the proposed hypothesis is that CD14⁺ cells infected by the EV71 virus might modulate the anti-EV71 adaptive immune response by inducing simultaneous T-cell activation.

Emerging Microbes and Infections (2013) 2, e44; doi:10.1038/emi.2013.44; published online 24 July 2013

Keywords: CD14⁺ cells; cytokines; enterovirus 71; neonatal rhesus monkey; Th1/Th2 response

INTRODUCTION

In recent years, frequent and widespread outbreaks of hand, foot and mouth disease in infants and young children have been reported in Asian-Pacific countries.^{1–4} Preliminary studies of the major pathogen enterovirus 71 (EV71), a member of the *Picornaviridae* family,⁵ have suggested that EV71 may be a major pathological cause of fatal hand, foot and mouth disease cases^{1,6–8} by inducing significant pathological changes in the central nervous system (CNS) that ultimately lead to neurogenic pulmonary failure.^{9,10} These neurological lesions and the subsequent severe sequelae that result from infection are believed to be a potential growing threat to child health and may be the largest risk to children since polio was 'eradicated'.^{8,11} Thus, studies of the pathogenic features of EV71, particularly its mechanism of pathogenesis and the associated immunopathogenesis in EV71-infected human tissues and cells, would contribute to a better understanding of the significance of this virus to public health.¹²

Despite the lack of understanding of the viral infection processes involved in the migration of the virus from primary infection sites, such as the mucosa in the respiratory or intestinal tracts, to the CNS via the circulation and peripheral nerves, previous studies have described potential pathogenic mechanisms of EV71.^{13–15} Dendritic cell (DC)-specific intercellular adhesion molecule-3-grabbing nonintegrin has been reported to be one of the specific EV71 receptors on the surface of immature human DCs.¹⁶ Other categories of scavenger receptors¹⁷ as well as P-selectin¹⁸ and Annexin II¹⁹ are usually expressed on the surface of monocytes, DCs and epithelial cells.^{20,21} Furthermore, EV71 has been shown to have the capacity to infect immature DCs, in which this virus can proliferate and then presumably migrate to associated organs and tissues such as the CNS.¹⁶

Additionally, high viral loads have been detected in the lymphocytes of EV71-infected patients and animal models.^{22,23} These data suggest that an interaction exists between EV71 and immunocytes during the EV71 infection process. This process likely follows the logical progression of typical pathological changes in CNS tissues and other organs, such as the lungs, and the corresponding inflammatory reactions induced by abnormally functioning immunocytes.1,12,24 In fact, abnormal increases in the level of some inflammatory factors, such as interleukin-6 (IL-6) and interferon- γ (IFN- γ), have been observed in both lethal EV71 clinical cases and in animal model studies of EV71 infection.^{25–27} Thus, further investigation of the interaction between the virus and immunocytes during the EV71 infection process would shed light on the pathogenesis of EV71 infection. In this paper, the impact of EV71 infection on CD14⁺ cells and the immune activity of T lymphocytes are described. The observations are based on the infection of CD14⁺ cells by EV71 in a neonatal rhesus monkey model that was previously established in our laboratory. In this model, the pathogenic process of EV71 infection can be monitored based on clinical manifestations, viral load and tissue pathogenic changes.²³ The corresponding modulatory and stimulatory functions of this infection on the immune system were investigated with in vivo and in vitro experiments.

MATERIALS AND METHODS

Virus and cells

The FY-23 subgenotype C4 strain of the EV71 virus was isolated from an infected male child with clinical symptoms of severe cardiopulmonary collapse during an epidemic in Fuyang, China, in 2008 (GenBank accession number: EU812515.1).²⁸ The virus was grown

Institute of Medical Biology, Chinese Academy of Medicine Science and Peking Union Medical College, Kunming 650118, China

*These authors contributed equally to this work.

Correspondence: QH Li

E-mail: imbcams.lq@gmail.com

Received 27 February 2013; Revised 15 May 2013; Accepted 14 June 2013

npg

in Vero cells (ATCC, Manassas, VA, USA), as previously described.²³ The Vero cells were maintained in Dulbecco's modified Eagle's medium (HyClone, Logan, UT, USA) with 10% fetal bovine serum (Gibco, Grand Island, NY, USA).

Neonatal rhesus monkeys

All animal work was conducted according to the relevant national and international guidelines. The Office of Laboratory Animal Management of Yunnan Province, China, approved the experimental procedures used with these animals (approval number: SCXK (Dian) 2011-0005). All animals were kept in isolation for 2 weeks before the initiation of the study. Each newborn monkey and its mother were kept in a single cage and were fed according to the guidelines of the Committee on Experimental Animals at the Institute of Medical Biology, Chinese Academy of Medical Sciences.²⁹ A neutralization test was conducted to confirm that the monkeys did not have antibodies against EV71 prior to the experimental infections.²³ In accordance with the recommendations of the Weatherall report, the experiments were approved by Experimental Animal Welfare Ethics Committee of the Institute of Medical Biology (approval number: YISHENGLUNZI [2011] 15).

A total of 12 healthy newborn rhesus monkeys with an average weight of 300 ± 350 g and an average age of 1–1.5 months were divided into two groups, with three monkeys in experimental group one and nine monkeys in experimental group 2 (including three monkeys in control group (transfused the normal CD14⁺ cells from other monkeys), three monkeys in donor group (separated the peripheral blood mononuclear cells (PBMCs), infected CD14⁺ cells with EV71 *in vitro*, and then transfused back the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys in non-donor group (transfused the EV71-infected CD14⁺ cells) and three monkeys (transfused the EV71-infected CD14⁺ c

In experimental group 1, the monkeys were infected with EV71 ($10^{4.5}$ cell culture infective dose 50% (CCID₅₀)/monkey) via the respiratory tract.²³ Briefly, the monkeys were anesthetized with ketamine (10 mg/kg of body weight; Phoenix Pharmaceuticals, St Joseph, MO, USA) and then infected using a bronchoscope wedged into the desired trachea. The virus, in 2 mL of sterile saline, was instilled into the trachea via the biopsy channel of the bronchoscope. The three neonates in experimental group 1 were killer by over anesthetization at day 5 post-infection (p.i.) for analysis of EV71-infected CD14⁺ cells.

The monkeys in experimental group 2 were used to provide PBMCs and were used in the transfusion experiment but were not sacrificed. Briefly, CD4⁺, CD8⁺, CD14⁺ and CD20⁺ cells were separated from the PBMCs collected from experimental group 2. Cultured CD14⁺ cells were infected with EV71 for the dynamic analysis of viral proliferation or for transfusion back into three original donors or three non-donor monkeys.

Cell isolation, separation and culture

PBMCs, lymph monocytes and spleen monocytes were isolated from whole blood, the axillary lymph nodes and the spleen, respectively, by density gradient centrifugation over Lymphoprep (Ficoll-Paque PREMIUM; GE Healthcare, Piscataway, NJ, USA). The cells were counted, assayed for viability via trypan blue exclusion, and separated into CD20⁺, CD14⁺, CD4⁺ and CD8⁺ populations using specific immunoadsorption (monoclonal antibody-coated magnetic beads; Miltenyi Biotec, Bergisch Gladbach, Germany) and flow cytometry. The marker-positive cells and marker-negative cells in the population were cultured at a density of 1.0×10^7 cells/mL in RPMI 1640 (HyClone, Logan, UT, USA) with 10% fetal bovine serum (Gibco), 100 U/mL penicillin, 100 $\mu g/mL$ streptomycin, 30 ng/mL granulocytemacrophage colony-stimulating factor and 10 ng/mL IL-4, at 37 $^\circ C$ in 5% CO_2.

Isolation and titration of the virus

The virus samples harvested from cell cultures or isolates of different cell populations (CD4⁺, CD8⁺, CD14⁺ and CD20⁺ from infected neonates) were analyzed with a microtitration assay. Briefly, the virus sample was diluted sequentially 10-fold and used to inoculate monolayers of Vero cells in a 96-well plate with a volume of 50 μ L/well and eight wells for each dilution. After 72 h of incubation at 37 °C post-inoculation, the extent of the cytopathic effect in the inoculated cells was observed to determine the viral titer.³⁰

Extraction of viral RNA and quantitative reverse transcription polymerase chain reaction (qRT-PCR) amplification

Viral RNA was extracted from the cells and tissues of the experimental animals using a Qiagen RNeasy Mini Kit (Qiagen, Hilden, Germany). The viral loads were quantified relative to a standard RNA copy number by real-time real-time RT-PCR analysis, as previously described.³⁰

Immunofluorescence analysis of cells and antigens

The tissue samples from each infected monkey were fixed in formalin, dehydrated, embedded, sectioned, placed on glass slides and fixed in paraformaldehyde as previously described.³⁰ The cell samples, including PBMCs and spleen lymphocytes from infected monkeys in experimental group 1, were washed with phosphate-buffered saline (PBS), resuspended, smeared on a glass plate, fixed with acetone and dried.³¹ The EV71 antigen was detected using a mouse anti-enterovirus 71 monoclonal antibody (Chemicon, Temecula, CA, USA) and antimouse IgG-rhodamine antibodies (Sigma, Deisenhofen, Germany). CD14⁺ cells were detected using a labeled anti-CD14 antibody (BD Biosciences, San Jose, CA, USA). The staining procedure was performed according to a standard protocol.³¹ The imaging of labeled samples was performed with a Nikon C1 laser scanning confocal microscope system (Nikon, Tokyo, Japan). The acquisition, storage and analysis of the data were performed using EZ-C1 viewer software from Nikon.

EV71 infects CD14⁺ cells in vitro

CD14⁺ cells $(1.0 \times 10^5$ cells/well) from the normal neonates of experimental group 2 were cultured for 24 h at 37 °C in 5% CO₂ and then infected with EV71 multiplicity of infection (MOI)=1 *in vitro*. Briefly, the cells were washed twice, infected with EV71, and then washed again prior to culturing at 37 °C. The supernatants and cells were collected at 24 h p.i. 200 µL of supernatant from the infected cells was used for cytokine detection by cytometric bead array (CBA) as described below. The cells were harvested after three freeze–thaw cycles to determine the viral loads by virus titration and qRT-PCR.

T lymphocyte proliferation assay

The supernatants of EV71-infected CD14⁺ cells were harvested at 24 h p.i. (as described above) and then added to T cells (purified using anti-CD3 monoclonal antibody-coated magnetic beads, 1.0×10^5 cells/well). The stimulated T cells were divided into two parts for experiments. One part is for cytokines assay. After 24, 48 and 72 h of incubation at 37 °C, the cytokines were detected by CBA as described below. And the other part of cells were incubated for 48, 72 or 96 h at 37 °C in 5% CO₂, pulsed with ³H-thymidine (1 µCi/well; NEN/DuPont, Boston, MA, USA) for 8 h, and harvested. The results are expressed as counts per minute of ³H-thymidine incorporation and represent the mean of triplicate cultures.

Culture supernatants and sera from the transfused monkeys were collected for use in detection assays targeting IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, tumor-necrosis factor- α (TNF- α) and IFN- γ . These assays were conducted simultaneously using a Th1/Th2 cytokine cytometric bead array kit specific for non-human primate (BD Biosciences, San Diego, CA, USA).³² The assay was conducted following the manufacturer's protocol. Briefly, a mixture of the anti-cytokine beads was added to the supernatant or serum samples, and these samples were incubated with the included phycoerythrin (PE) detection reagent in the dark at room temperature for 3 h, and then washed for twice. The intensity of the fluorescence signal was acquired on a fluorescence-activated cell sorter flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed using CBA software (BD Biosciences, San Jose, CA, USA). The results of the experiments have excluded the levels of previously added IL-4, according to the control.

Transfusion experiment

CD14⁺ cells (2×10⁵ cells) collected from each of the three normal neonates in experimental group 2 were infected with EV71 (MOI=1) *in vitro*. At 24 h p.i., the *in vitro*-infected CD14⁺ cells (2×10⁵ cells) were collected by centrifugation and washed with PBS three times. Half of these CD14⁺ cells were transfused back into the three original donor monkeys (auto-transfusion), and the other half of the cells were transfused into three additional monkeys (allo-transfusion).³³ As a negative control, three additional monkeys were monitored daily for body temperature and general health status. PBMCs were taken from all the monkeys at day 5 post-transfusion, incubated for 24 h and stimulated with EV71 VP1 peptide prior to intracellular cytokine staining and flow cytometry to determine the percentage of cells producing IFN- γ .

Intracellular cytokine staining with flow cytometry

The intracellular cytokine staining assay was performed using freshly isolated PBMCs from transfused or normal monkeys. The cells were stimulated with EV71 antigen (2 ng/mL) for 4 h at 37 °C. The negative controls included cells incubated without peptide. Brefeldin A (10 µg/mL; Sigma, St Louis, MO, USA) was added according to the method described in detail by Karlsson *et al.*³⁴ All the cells were washed and stained for flow cytometry with fluorescein isothiocyanate-conjugated anti-IFN- γ (BD Biosciences, San Jose, CA, USA) and PE-conjugated anti-CD3 (BD Biosciences, San Jose, CA, USA) for 30 min at 4 °C. After staining, the cells were washed, fixed in 1% paraformaldehyde, and collected with a FACSCalibur instrument using Cell Quest software (BD Biosciences, San Jose, CA, USA). The proportion of cells producing IFN- γ was recorded.

Statistical analysis

The data were expressed as the means and standard deviations. Individual experiments were repeated three times per sample. GraphPad Prism software (San Diego, CA, USA) was used for the statistical analyses. The differences between the two groups were evaluated using one-way analysis of variance. A *P* value of <0.05 was considered significant.

RESULTS

EV71 has the ability to infect CD14⁺ cells during the infection of neonatal rhesus monkeys

As demonstrated in our previous studies, an EV71 viremia peak is typically present from days 5 to 8 p.i. in the neonatal monkey model, followed by sustained high viral loads from days 7 to 10 p.i. in the CNS and other organs, including brown adipose tissue and lymph nodes.²³ qRT-PCR amplification of viral RNA extracted from the blood samples of monkeys in experimental group 1 collected on day 5 p.i. indicated that EV71 was present in PBMCs (Figure 1A). By contrast, no viruses were observed in the serum, erythrocytes (red blood cells) or platelets (Figure 1A). The sampled PBMCs of these infected monkeys were immobilized on slides for analysis by confocal fluorescence microscopy using an anti-EV71 antibody and anti-CD14, CD4, CD8 and CD20 fluorescent antibodies. EV71 and CD14 fluorescence were observed within the same cells among PBMCs obtained at day 5 p.i. (Figure 1B). However, no EV71 fluorescence was observed in CD4⁺, CD8⁺ and CD20⁺ cells (Supplementary Table S1). Because EV71 is delivered via a respiratory tract spray in our established neonatal monkey model, this study highlights the relationship between CD14⁺ cells and EV71 antigen expression in the trachea, axillary lymph nodes and spleens of infected animals sacrificed at day 5 p.i. The colocalization of anti-EV71 and anti-CD14 antibodies was observed in the trachea, axillary lymph nodes and spleen tissue (Figure 1B). To confirm these observations, viral microtitration and qRT-PCR were used to detect the virus in Vero cells cocultured with CD14⁺ cells isolated from either the PBMCs or lymph nodes of infected animals and purified with flow cytometry. The Vero cells cocultured with CD14⁺ cells were positive for virus by both methods (Figure 1C). Together, these findings are sufficient to suggest that EV71 has the ability to infect host CD14⁺ cells. In these cells, the virus might be maintained and could subsequently migrate to tissues and/or organs in infected neonatal monkeys.

Dynamic profile of EV71 proliferation in CD14⁺ cell culture

To explore the potential mechanism of the EV71 infection of CD14⁺ cells in infected neonatal monkeys, the dynamic proliferation of the virus in infected CD14⁺ cells and other PBMCs from normal monkeys in experimental group 2 was assessed *in vitro*. The CD14⁺ cells and other cells, including CD4⁺, CD8⁺ and CD20⁺ cells, were infected by EV71 at an MOI of 0.5–1, and aliquots were collected every 4 h for viral titration. The results collectively suggest that EV71 has a distinct proliferation profile in CD14⁺ cells (Figure 2A). This tendency was confirmed by qRT-PCR amplification (Figure 2B). These findings imply that EV71 proliferates in CD14⁺ cells.

EV71 infection modulates the cytokine profile of CD14⁺ cells

Based on previously published data, CD14⁺ cells are a type of active immune cell that are capable of modulating both innate and adaptive immune responses by releasing various cytokines.35,36 Our hypothesis-that EV71 infects and proliferates inside CD14⁺ cells-suggests that EV71 might induce an abnormal inflammatory response in vivo by interfering with the regulation of the immune response by CD14⁺ cells. The determination of the cytokine profile of CD14⁺ cells isolated from infected animals provided evidence that EV71 interferes with the immune response. These CD14⁺ cells cultured in vitro produced higher levels of several cytokines related to immune regulation, including IL-8, IL-4 and IL-6, compared with the control cells from normal monkeys (Figure 3A). To confirm this observation, the cytokine levels in the supernatants of cultured CD14⁺ cells isolated from normal monkeys and infected by EV71 in vitro were detected by cytometry. The results indicate that higher levels of IL-8, IL-4 and IL-6 are produced by infected CD14⁺ cells than by negative control cells (Figure 3B). Higher IL-6 levels in the blood and CSF are usually observed in patients with fatal EV71 infections. The data suggest that IL-8 is in fact involved in inflammatory responses.³⁷ However,



EV71-infected CD14⁺ cells activate immune response JJ Wang *et al*



Figure 1 CD14⁺ monocytes are associated with EV71 infection. (**A**) Viral loads in various cells or components from the blood of infected rhesus monkeys. Viral RNA was extracted and measured using the Taqman-based real-time qPCR assay. *P* values of PBMC and spleen cells *vs.* serum, RBC and platelets. (**B**) Confocal fluorescence microscopy of CD14⁺ cells and EV71 antigen in PBMCs, trachea, axillary lymph nodes and spleen from EV71-infected neonatal monkeys. (**C**) Viral load from CD4⁺, CD8⁺, CD14⁺ and CD20⁺ cells of EV71-infected neonatal monkeys. Viral titer data are shown in IgCCID₅₀ scale. *P* value of the viral load of CD14⁺ cells *vs.* the viral load of CD4⁺ and CD8⁺ cells. Samples were collected from EV71-infected neonatal monkeys (experimental group 1, *n*=3) at day 5 p.i. Three independent experiments were performed. RBC, red blood cell; qPCR, quantitative polymerase chain reaction.

whether the upregulation of IL-8 expression in infected CD14⁺ cells is related to the pathogenesis of EV71 is not completely clear.

EV71-infected CD14⁺ cells stimulate the proliferation of T lymphocytes

After the removal of CD20⁺ cells, the majority of the remaining CD14⁺ cells are monocytes and partially immature DCs,³⁸ which are believed to be capable of activating lymphocytes upon exposure to viral infection.^{39,40} Based on this understanding, we cultured T cells with the supernatant of EV71-infected CD14⁺ cells and subsequently performed T lymphocyte proliferation assays. In parallel, the supernatants of lipopolysaccharide-stimulated CD14⁺ cells and non-stimulated (negative) cells were used as controls to determine the impact of CD14⁺ cells on T-cell proliferation. The results indicate that the

supernatant of EV71-infected CD14⁺ cells has a stimulatory effect on T lymphocyte proliferation that is equivalent to the effect of the lipopolysaccharide control relative to the negative control (Figure 4A). The detection of cytokines in the supernatant of T lymphocytes cultured with the supernatant of EV71-infected CD14⁺ cells indicated a significant increase in TNF- α release after 24 h of culture (Figure 4B). Additionally, the level of IL-6 release also tended to slightly increase after 24 h, whereas IL-4 release tended to significantly increase after 48 h and reached its peak at 72 h (Figure 4B). The levels of other cytokines exhibited no clear differences relative to the levels in the negative control group (with the supernatant of EV71-infected CD14⁺ cells and without T lymphocytes) (Figure 4B). These findings suggest a potential triggering effect of EV71-infected CD14⁺ cells on T lymphocyte proliferation.



Figure 2 Dynamic profile of EV71 proliferation in CD14⁺ cells *in vitro*. The proliferation of viruses in CD14⁺ cells from normal monkeys (experimental group 2, n=3) measured by virus titration (**A**) and qRT-PCR assay (**B**) from 0 to 48 h p.i. *in vitro*. The values are the average of three independent experiments.

EV71-infected CD14⁺ cells activate a specific immune response against EV71 infection *in vivo*

Our results indicate that EV71-infected CD14⁺ cells have the ability to stimulate T lymphocyte proliferation, which leads directly to the question as to whether this T lymphocyte proliferation, exhibited by the tendency toward a Th2 response, is significant to the specific anti-EV71 response of the immune system of the monkeys. We decided to study the potential relationship between EV71-infected CD14⁺ cells and the specific immune response in vivo. When comparing the negative control and the non-donor monkeys in experimental group 2 according to major histocompatibility complex differences, a higher percentage of cells producing IFN- γ was found for the three donor monkeys back-transfused with EV71-infected CD14⁺ cells (Figure 5); however, an IFN- γ -specific immune response targeting a specific antigenic peptide in EV71 VP1 was not observed within 5 days after the same quantity of allogeneic EV71-infected CD14⁺ cells were transfused into non-donor monkeys (Figure 5). These results imply that the potential function of EV71-infected CD14⁺ cells in the infection process in monkeys is related not only to viral migration to tissues and organs in the infected monkeys, but also to the activation of the T lymphocyte response and the subsequent development of an adaptive anti-EV71 immune response in the monkeys.

DISCUSSION

EV71, a member of the family *Picornaviridae*, is known to enter the human body via the mucosa of the respiratory or intestinal tracts, where infection is initiated.^{15,41} The details of EV71 pathogenesis have remained unclear; however, based on available studies of other enteroviruses, the primary site of EV71 proliferation after entry into the human body is assumed to be the reticuloendothelial system.^{42,43} Furthermore, evidence suggests that EV71 has the ability to infect cells of the lymphatic system, such as human peripheral blood monocytes⁴⁴ and immature DCs.¹⁶ EV71 receptor studies have demonstrated that DC-specific intercellular adhesion molecule-3-grabbing non-integrin, scavenger-II and P-selectin, among other receptors, expressed on the surfaces of monocytes, lymphocytes, DCs and epithelial cells, are capable of binding specifically to EV71.^{16–18} Taken together, these results suggest that after entry into the respiratory or intestinal tract mucosa, EV71 is taken up into the microcirculation of local tissues and subsequently enters cells via binding to surface-expressed receptors. Although the details of this biological event require further elucidation, our studies provide additional evidence to support this hypothesis. Similar with the reports of Dr Wang and his colleagues,⁴⁴ we also found that EV71 can infect PBMCs from rhesus monkeys. Furthermore, by separating PBMCs into different cell subsets, we



Figure 3 EV71-infected CD14⁺ cells stimulate cytokine production *in vitro*. (**A**) Detection of cytokines in the supernatants of CD14⁺ cells from EV71-infected monkeys (n=3) after 24 h of culturing *in vitro*. P value vs. control group (the supernatants of CD14⁺ cells from normal monkeys after 24 h of culturing). (**B**) Detection of cytokines in the supernatants of EV71-infected CD14⁺ cells after 24 h post-infection *in vitro*. P value vs. control group (the supernatants of CD14⁺ cells from normal monkeys after 24 h of culturing). (**B**) Detection of cytokines in the supernatants of EV71-infected CD14⁺ cells after 24 h post-infection *in vitro*. P value vs. control group (the supernatants of normal CD14⁺ cells after 24 h of culturing). The cytokines (IL-4, IL-6, IL-8, IL-10, TNF- α and IFN- γ) were measured using BD System kits in accordance with the section on 'Materials and methods'. Three independent experiments were performed.

EV71-infected CD14⁺ cells activate immune response JJ Wang *et al*



Figure 4 EV71-infected CD14⁺ cells induce the proliferation of T lymphocytes. (**A**) The proliferation of T lymphocytes cultured with the supernatants of EV71-infected CD14⁺ cells was measured by ³H-thymidine. Cultured CD14⁺ cells were infected by EV71 (MOI=1) for 24 h. The supernatants were collected and added into normal T lymphocytes from the same monkeys. The L, V and N groups were treated with LPS (10 ng/mL, L group), infected with EV71 (MOI=1, V group) or received no treatment (N group), respectively. (**B**) Detection of cytokines in the supernatants of EV71-infected CD14⁺ cells cultured with normal donor T lymphocytes (from experimental group 2) *in vitro*. Cultured CD14⁺ cells were infected with EV71 (MOI=1) for 24 h. The supernatants were collected and added into normal T lymphocytes cultures from the same monkeys. The cytokines (IL-2, IL-4, IL-5, IL-6, TNF- α and IFN- γ) in the supernatants were measured at different time points using BD System kits. *P* value *vs.* control group (the supernatants of EV71-infected CD14⁺ cells after culturing). Three independent experiments were performed. LPS, lipopolysaccharide.

found EV71-infected CD14⁺ cells in the respiratory tract mucosal tissue of EV71-infected neonatal monkeys (Figure 1). Analysis of PBMCs and lymph nodes harvested at day 5 p.i. by confocal immunofluorescence microscopy further supports the hypothesis that EV71infected CD14⁺ cells enter the cardiovascular and lymphatic systems (Figure 1). These results suggest that EV71 has the ability to infect CD14⁺ cells and to subsequently migrate to other target organs or tissues. In our previous studies of EV71 infection in the neonatal monkey model, the peak viral load during the EV71 infection process occurred in the axillary lymph nodes, submaxillary lymph nodes and lung lymph nodes from days 5 to 8 p.i., during which time viral viremia develops.²³ The peak viral loads occur in certain tissues and organs, such as the CNS and lungs, on day 7 p.i.²³ This linear variation in the viral load, increasing with time, provides further support for the hypothesis that EV71 primarily migrates via the blood. Again, the detection of EV71 genomes in blood samples taken at day 5 p.i. indicated the presence of EV71 in PBMCs (Figure 1A). These observations, taken together, are indicative of EV71 migration via host CD14⁺ cells throughout the body via circulation in the blood and lymphatic systems. The dynamic profile of EV71 proliferation in infected CD14⁺ cells cultured *in vitro* further supports the capacity of EV71 to facilitate proliferation by infecting $\overline{CD14}^+$ cells (Figure 2). As a pattern recognition molecule, CD14 has a central role in innate immunity and is a major hallmark of monocytes and immature DCs,⁴⁵ which are capable of stimulating and regulating innate and adaptive immune responses through various pathways.^{35,36} Our data suggest that the CD14⁺ cells modulated the expression profiles of some cytokines after infection by EV71. Thus, EV71-infected CD14⁺ cells are hypothesized to have the ability to stimulate a T-cell response. Interestingly, our results indicate that when T cells are cultured with the supernatant of EV71-infected CD14⁺ cells, the T cells proliferate and the production of some functional cytokines increases (Figure 4). Although further research is needed to determine the detailed mechanism of this process, these results suggest that EV71infected CD14⁺ cells are the basis of one potential pathway for the stimulation of T cell activation following viral infection.

EV71-infected patients and animals provide evidence that EV71 infection may frequently lead to the increased release of particular



Figure 5 EV71-infected CD14+ cells induced a specific anti-EV71 immune response in monkeys. The CD14⁺ cells from three normal monkeys were infected by EV71 (MOI=1) *in vitro*. After 24 h p.i., EV71-infected CD14⁺ cells were transfused either back into the same monkeys or into three non-donor monkeys in experimental group 2. PBMCs were collected from the transfused monkeys at 5 days post-transfusion. The percentages of cells producing IFN- γ in the sera of monkeys were determined using CFC as described in the section on 'Materials and methods'. *P* value *vs.* positively and negatively stimulated group. Three independent experiments were performed. CFC, cytokine flow cytometry.

pg

cytokines, such as IFN- γ and/or IL-6, into the blood or cerebrospinal fluid in infected individuals.^{25–27} Currently, whether the pathological changes induced by EV71 infection are actually involved in the immunopathogenic response is unknown. Because EV71 has the ability to infect CD14⁺ cells and impart immunological activation and immunoregulation capabilities, studying the impact of EV71-infected CD14⁺ cells on the immune system and the related immune response is of great importance. The increased proliferation of T cells cultured with the supernatant of EV71-infected CD14⁺ cells and the significant increases in TNF- α and IL-6 production are sufficient to indicate that the immune responses activated by EV71-infected CD14⁺ cells are biased toward a Th2 response (Figure 4). Such model is also suggested by some reports that EV71-infected patients and animals are characterized by an obvious increase in IL-6 release in the peripheral blood.²⁷ However, somewhat differing rates of IFN- γ release have been reported.²⁶ Thus, there may be a currently unknown association between EV71-infected CD14⁺ cells and the induced inflammatory response that is closely related to pathogenesis. Further exploration of this association will contribute to the overall understanding of EV71 pathogenesis.

ACKNOWLEDGMENTS

This work was supported by the National Basic Research Program (2011CB504903 and 2012CB518901), National Natural Sciences Foundation of China (81171573 and 31100127), the Yunnan Natural Science Foundation (2011FB116) and the Peking Union Medical Youth Found (2012J23).

- 1 Chan LG, Parashar UD, Lye MS et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. *Clin Infect Dis* 2000; **31**: 678–683.
- 2 Shimizu H, Utama A, Yoshii K *et al.* Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997–1998. *Jon J Infect Dis* 1999: **52**: 12–15.
- 3 Zhang Y, Tan XJ, Wang HY et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 2009; 44: 262–267.
- 4 Ahmad K. Hand, foot, and mouth disease outbreak reported in Singapore. Lancet 2000; 356: 1338.
- 5 Sim AC, Luhur A, Tan TM, Chow VT, Poh CL. RNA interference against enterovirus 71 infection. *Virology* 2005; 341: 72–79.
- 6 Ooi MH, Solomon T, Podin Y et al. Evaluation of different clinical sample types in diagnosis of human enterovirus 71-associated hand-foot-and-mouth disease. J Clin Microbiol 2007; 45: 1858–1866.
- 7 Lin TY, Chang LY, Hsia SH *et al.* The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. *Clin Infect Dis* 2002; **34**(Suppl 2): S52–S57.
- 8 McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002; 26: 91–107.
- 9 Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 1999; 341: 936–942.
- 10 Wang SM, Liu CC, Tseng HW *et al.* Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. *Clin Infect Dis* 1999; **29**: 184–190.
- 11 da Silva EE, Winkler MT, Pallansch MA. Role of enterovirus 71 in acute flaccid paralysis after the eradication of poliovirus in Brazil. *Emerg Infect Dis* 1996; **2**: 231–233.
- 12 Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. *Lancet Infect Dis* 2010; 10: 778–790.
- 13 Wong KT, Munisamy B, Ong KC *et al.* The distribution of inflammation and virus in human enterovirus 71 encephalomyelitis suggests possible viral spread by neural pathways. *J Neuropathol Exp Neurol* 2008; **67**: 162–169.
- 14 Chen CS, Yao YC, Lin SC et al. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J Virol 2007; 81: 8996–9003.
- 15 Nagata N, Shimizu H, Ami Y *et al.* Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. *J Med Virol* 2002; 67: 207–216.
- 16 Lin YW, Wang SW, Tung YY, Chen SH. Enterovirus 71 infection of human dendritic cells. *Exp Biol Med (Maywood)* 2009; 234: 1166–1173.

- 17 Yamayoshi S, Yamashita Y, Li J *et al.* Scavenger receptor B2 is a cellular receptor for enterovirus 71. *Nat Med* 2009; 15: 798–801.
- 18 Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human Pselectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. *Nat Med* 2009; 15: 794–797.
- 19 Yang SL, Chou YT, Wu CN, Ho MS. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol 2011; 85: 11809–11820.
- 20 Laszik Z, Jansen PJ, Cummings RD, Tedder TF, McEver RP, Moore KL. P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid, and dendritic lineage and in some nonhematopoietic cells. *Blood* 1996; 88: 3010–3021.
- 21 Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. *Trends Cell Biol* 2003; 13: 137–145.
- 22 Chumakov M, Voroshilova M, Shindarov L et al. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 1979; 60: 329–340.
- 23 Liu L, Zhao H, Zhang Y et al. Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection. *Virology* 2011; 412: 91–100.
- 24 Lin TY, Hsia SH, Huang YC, Wu CT, Chang LY. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. *Clin Infect Dis* 2003; 36: 269–274.
- 25 Wang SM, Lei HY, Su LY *et al.* Cerebrospinal fluid cytokines in enterovirus 71 brain stem encephalitis and echovirus meningitis infections of varying severity. *Clin Microbiol Infect* 2007; **13**: 677–682.
- 26 Wang SM, Lei HY, Huang KJ et al. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis 2003; 188: 564–570.
- 27 Lin TY, Chang LY, Huang YC, Hsu KH, Chiu CH, Yang KD. Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. *Acta Paediatr* 2002; **91**: 632–635.
- 28 Ma SH, Liu JS, Wang JJ et al. Genetic analysis of the VP1 region of human enterovirus 71 strains isolated in Fuyang, China, during 2008. Virol Sinica 2009; 24: 162–170.
- 29 Gorska P. Principles in laboratory animal research for experimental purposes. *Med Sci Monit* 2000; 6: 171–180.
- 30 Zhang Y, Cui W, Liu L *et al.* Pathogenesis study of enterovirus 71 infection in rhesus monkeys. *Lab Invest* 2011; **91**: 1337–1350.
- 31 Hinuma Y, Konn M, Yamaguchi J, Wudarski DJ, Blakeslee JR Jr, Grace JT Jr. Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol 1967; 1: 1045–1051.
- 32 Chen R, Lowe L, Wilson JD *et al.* Simultaneous quantification of six human cytokines in a single sample using microparticle-based flow cytometric technology. *Clin Chem* 1999; **45**: 1693–1694.
- 33 Lopas H, Birndorf NI. Haemolysis and intravascular coagulation due to incompatible red cell transfusion in isoimmunized monkeys. Br J Haematol 1971; 21: 399–411.
- 34 Karlsson AC, Martin JN, Younger SR et al. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 2003; 283: 141–153.
- 35 Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol 2000; 164: 13–17.
- 36 Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004; 5: 971–974.
- 37 Gomez MI, Lee A, Reddy B et al. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat Med 2004; 10: 842–848.
- 38 Yamaguchi N, Fujimori Y, Fujibayashi Y et al. Interferon-gamma production by human cord blood monocyte-derived dendritic cells. Ann Hematol 2005; 84: 423–428.
- 39 Bhardwaj N, Bender A, Gonzalez N, Bui LK, Garrett MC, Steinman RM. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8⁺ T cells. *J Clin Invest* 1994; **94**: 797–807.
- 40 Kawamura K, Kadowaki N, Kitawaki T, Uchiyama T. Virus-stimulated plasmacytoid dendritic cells induce CD4⁺ cytotoxic regulatory T cells. *Blood* 2006; **107**: 1031–1038.
- 41 Ryu WS, Kang B, Hong J, Hwang S, Kim J, Cheon DS. Clinical and etiological characteristics of enterovirus 71-related diseases during a recent 2-year period in Korea. J Clin Microbiol 2010; 48: 2490–2494.
- 42 Boping Z, Chenrong L. *Enterovirus 71 hand mouth foot disease*. Beijing: The People's Medical Publishing House, 2009.
- 43 Wang YF, Chou CT, Lei HY et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol 2004; 78: 7916–7924.
- 44 Wang SM, Chen IC, Su LY, Huang KJ, Lei HY, Liu CC. Enterovirus 71 infection of monocytes with antibody-dependent enhancement. *Clin Vaccine Immunol* 2010; 17: 1517–1523.
- 45 Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. *J Immunol* 2005; **175**: 1373–1381.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported license. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0

Supplementary Information for this article can be found on Emerging Microbes & Infections's website (http://www.nature.com/EMI/).